Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401830 · ClinicalTrials.gov registry record · Phase 2
Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.
A Phase 2 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT00401830 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 159 participants.
The verdict
NCT00401830, a Phase 2 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome.
Interventions
- OTHER Placebo
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401830
The ClinicalTrials.gov registry entry for NCT00401830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00401830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401830 about?
NCT00401830 is a clinical study titled "Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.". This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome.
What is the current status of trial NCT00401830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2006-10. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00401830?
The interventions under investigation include: Placebo (OTHER), Lacosamide (DRUG).
Who is sponsoring clinical trial NCT00401830?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.